Thallium(I) Tropolonates: Synthesis, Structure, Spectral Characteristics, and Antimicrobial Activity Compared to Lead(II) and Bismuth(III) Analogues.

Synthesis, single-crystal X-ray determination diffraction and FT-IR, NMR (H, C, F and Tl), UV-vis, and luminescence spectra characteristics were described for series of thallium(I) compounds: thallium(I) triflate (Tl(OTf)), 1:1 co-crystals of thallium(I) triflate and tropolone (Htrop), Tl(OTf)·Htrop, as well as simple thallium(I) chelates: Tl(trop) (), Tl(5-metrop) (), Tl(hino) (), with Htrop, 5-methyltropolone (5-meHtrop), 4-isopropyltropolone (hinokitiol, Hhino), respectively, and additionally more complex {Tl@[Tl(hino)]}(OTf) () compound. Comparison of their antimicrobial activity with selected lead(II) and bismuth(III) analogs and free ligands showed that only bismuth(III) complexes demonstrated significant antimicrobial activity, from two- to fivefold larger than the free ligands.

Separation of Radionuclides from Spent Decontamination Fluids via Adsorption onto Titanium Dioxide Nanotubes after Photocatalytic Degradation.

A one-step process combining the photocatalytic degradation of radionuclide complexes and the adsorption of liberated radionuclides on titanium dioxide nanotubes was developed and tested for the purification of aqueous waste produced from chemical decontamination of nuclear power plant circuit components. Among the tested forms of TiO, only nanotubes exhibit both high photocatalytic activity and sorption ability, which support their application in a one-step purification process. The obtained results indicate that the photocatalytic degradation of complexes followed by the sorption of the radionuclides onto TiO nanotubes offers a promising route for treating spent decontamination fluids.

1,2-Benzenedithiol and Toluene-3,4-dithiol Arsenic(III) Complexes-Synthesis, Structure, Spectroscopic Characterization and Toxicological Studies.

A new group of arsenic(III) complexes with bidentate S,S-donor ligands, 1,2-benzenedithiol (Ph(SH)) and toluene-3,4-dithiol (MePh(SH)), were synthesized. The use of arsenic(III) iodide and bromide promoted the formation of neutral complexes (-) with the general formula AsX(LS) (X = I or Br, L = MePh or Ph). The crystal structures of these compounds were determined using single-crystal X-ray diffraction (scXRD).

At labeled substance P (5-11) as potential radiopharmaceutical for glioma treatment.

Introduction: The purposes of the present work were to label substance P (5-11) with At using a rhodium(III) complex with a bifunctional ligand-2-(1,5,9,13-tetrathiacyclohexadecan-3-yloxy)acetic acid ([16aneS]-COOH) and to assess the in vitro stability and toxicity of the obtained radiobioconjugate.

Methods: Two approaches were evaluated to obtain I/At-Rh[16aneS]-SP radiobioconjugates, based on 2-step and 1-step syntheses. In the first method I/At-Rh[16aneS]-COOH complexes were obtained that required further coupling to a biomolecule.

Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals.

Introduction: The heavy halogen (211)At is of great interest for targeted radiotherapy because it decays by the emission of short-range, high-energy α-particles. However, many astatine compounds that have been synthesized are unstable in vivo, providing motivation for seeking other (211)At labeling strategies. One relatively unexplored approach is to utilize prosthetic groups based on astatinated rhodium (III) complex stabilized with a tetrathioether macrocyclic ligand - Rh[16aneS(4)-diol](211)At.